Extramedullary disease and targeted therapies for hematological malignancies - Is the association real?

Annals of Oncology

Volumn 18, Issue 1, 2007, Pages 7-12

  Raanani, P ^a   Shpilberg, O ^a   Ben Bassat, I ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

ATRA; Extramedullary; Imatinib; Targeted therapy; Thalidomide

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CYTARABINE; DEXAMETHASONE; IMATINIB; INTERFERON; RETINOIC ACID; RETINOID DERIVATIVE; STEROID; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLAST CELL CRISIS; BLOOD BRAIN BARRIER; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG TRANSPORT; DRUG TREATMENT FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKOCYTOSIS; LYMPHADENOPATHY; MONOTHERAPY; MULTIPLE MYELOMA; NONHUMAN; PELVIS TUMOR; PLASMACYTOSIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SECOND CANCER; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKEMIC INFILTRATION; MULTIPLE MYELOMA;

EID: 33846499100     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl129     Document Type: Review

References (62)

1. Marra R, Stori S, Pagano L et al. Central nervous system acute promyelocytic leukaemia: A report of three cases. Haematologia (Budap) 1989; 22: 195-199.
2. Brown DM, Kimura AE, Ossoinig KC et al. Acute promyelocytic infiltration of the optic nerve treated by oral trans-retinoic acid. Ophthalmology 1992; 99: 1463-1467.
3. Giralt S, O'Brien S, Weeks E et al. Leukemia cutis in acute promyelocytic leukemia: Report of three cases after treatment with all-trans retinoic acid. Leuk Lymphoma 1994; 14: 453-456.
4. Lederman CA, Weisberger J, Seiter K et al. Differentiation of extramedullary acute promyelocytic leukemia by all-trans-retinoic acid. Leuk Lymphoma 1995; 18: 189-193.
5. Wiernik PH, De Bellis R, Muxi P et al. Extramedullary acute promyelocytic leukemia. Cancer 1996; 78: 2510-2514.
6. Currie J, Chee YL, Culligan DJ. Central nervous system relapse in acute promyelocytic leukaemia treated with ATRA. Br J Haematol 1997; 99: 469.
7. Maloisel F, Kurtz JE, Oberling F. Extramedullary acute promyelocytic leukemia. Cancer 1997; 79: 2263-2264.
8. Martino B, Vincelli I, Marino A et al. Meningeal relapse in a patient with acute promyelocytic leukaemia treated with all-trans retinoic acid. Br J Haematol 1998; 100: 606-607.
9. Thomas X, Fiere D, Archimbaud E. Persistence of retinoic acid sensitivity in relapsed acute promyelocytic leukemia with extramedullary involvement. Leukemia 1994; 8: 520-521.
10. Weiss MA, Warrell RP Jr. Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies. Cancer 1994; 74: 1882-1886.
11. Benekli M, Savas MC, Haznedaroglu IC et al. Two cases of extramedullary acute promyelocytic leukemia. Cancer 1995; 76: 151-152.
12. Selleri C, Pane F, Notaro R et al. All-trans-retinoic acid (ATRA) responsive skin relapses of acute promyelocytic leukaemia followed by ATRA-induced pseudotumour cerebri. Br J Haematol 1996; 92: 937-940.
13. Liso V, Specchia G, Pogliani EM et al. Extramedullary involvement in patients with acute promyelocytic leukemia: A report of seven cases. Cancer 1998; 83: 1522-1528.
14. Evans GD, Grimwade DJ. Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 1999; 33: 219-229.
15. Galimberti S, Papineschi F, Carmignani A et al. Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplant 1999; 24: 345-348.
16. Ko BS, Tang JL, Chen YC et al. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia the occurrence of retinoic acid syndrome is a risk factor. Leukemia 1999; 13: 1406-1408.
17. Mesa JR, Espinosa E, Losada R et al. Parotid and central nervous system relapse during complete hematologic remission in acute promyelocytic leukemia. Haematologica 1999; 84: 565-566.
18. Au WY, Ma SK, Ooi C et al. Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission. J Clin Oncol 2000; 18: 3435-3437.
19. Sanz MA, Larrea L, Sanz G et al. Cutaneous promyelocytic sarcoma at sites of vascular access and marrow aspiration. A characteristic localization of chloromas in acute promyelocytic leukemia? Haematologica 2000; 85: 758-762.
20. Mathews V, Balasubramanian P, Shaji RV et al. Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide. Br J Haematol 2001; 113: 257-258.
21. Specchia G, LoCoco F, Vignetti M et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: A report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001; 19: 4023-4028.
22. Burry LD, Seki JT. CNS relapses of acute promyelocytic leukemia after all-trans retinoic acid. Ann Pharmacother 2002; 36: 1900-1906.
23. Breccia M, Petti MC, Testi AM et al. Ear involvement in acute promyelocytic leukemia at relapse: A disease-associated sanctuary'? Leukemia 2002; 16: 1127-1130.
24. Patriarca F, Fili C, Geromin A et al. Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia. Eur J Haematol 2002; 68: 310-313.
25. Disel U, Yavuz S, Paydas S et al. Extramedullary relapse in the pleura in acute promyelocytic leukemia. Leuk Lymphoma 2003; 44: 189-191.
26. Bae SH, Ryoo HM, Cho HS et al. Meningeal relapse in a patient with acute promyelocytic leukemia: A case report and review of the literature. J Korean Med Sci 2004; 19: 311-314.
27. Tsimberidou AM, Estey E, Whitman GJ et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: Successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004; 28: 991-994.
28. de Botton S, Sanz MA, Chevret S et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006; 20: 35-41.
29. Breccia M, Carmosino I, Diverio D et al. Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count. Br J Haematol 2003; 120: 266-270.
30. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003; 17: 1454-1463.
31. Di Noto R, Lo Prado C, Schiavone EM et al. All-trans retinoic acid (ATRA) and the regulation of adhesion molecules in acute myeloid leukemia. Leuk Lymphoma 1996; 21: 201-209.
32. Marchetti M, Falanga A, Giovanelli S et al. All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol 1996; 93: 360-366.
33. de Gentile A, Toubert ME, Dubois C et al. Induction of high-affinity GM-CSF receptors during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1994; 8: 1758-1762.
34. Muindi JR, Frankel SR, Huselton C et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992; 52: 2138-2142.
35. Kwong YL, Au WY, Chim CS et al. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66: 274-279.
36. Zhang P, Wang S, Hu L et al. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide - an analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi 2000; 21: 67-70.
37. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345-351.
38. Rosinol L, Cibeira MT, Blade J et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832-836.
39. Juliusson G, Celsing F, Turesson I et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
40. Blade J, Perales M, Rosinol L et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113: 422-424.
41. Myers B, Grimley C, Crouch D et al. Lack of response to thalidomide in plasmacytomas. Br J Haematol 2001; 115: 234.
42. Avigdor A, Raanani P, Levi I et al. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 2001; 42: 683-687.
43. Anagnostopoulos A, Hamilos G, Zorzou MP et al. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk Lymphoma 2004; 45: 113-116.
44. Alexandrescu DT, Koulova L, Wiemik PH. Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: A case report and review of the literature. Clin Exp Dermatol 2005; 30: 391-394.
45. Biagi JJ, Mileshkin L, Grigg AP et al. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001; 28: 1145-1150.
46. Terpos E, Rezvani K, Basu S et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005; 75: 376-383.
47. Gonzalez-Porras JR, Gonzalez M, Garcia-Sanz R et al. Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. Br J Haematol 2002; 119: 883-884.
48. del Giglio A, Weinschenker P, Manhani AR et al. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. South Med J 2005; 98: 238-240.
49. Patriarca F, Prosdocimo S, Tomadini V et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005; 90: 278-279.
50. Paubelle E, Coppo P, Garderet L et al. Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: Possible enhancement of graft-vs-tumor effect. Leukemia 2005; 19: 1702-1704.
51. Rosinol L, Cibeira MT, Uriburu C et al. Bortezomib: An effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006; 76: 405-408.
52. Breccia M, Nanni M, Mancini F et al. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib. Haematologica 2004; 89: ECR11.
53. Smaradottir A, Kapur D, Bilgrami S. Unusual extramedullary relapse of CML. Ann Oncol 2004; 15: 1296-1297.
54. Beyazit Y, Aksu S, Kekilli M et al. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia. Am J Hematol 2005; 79: 79-80.
55. Rosario Cavalheiro RD, Vicari P, Maria MF et al. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy. Am J Hematol 2006; 81: 76-77.
56. Petzer AL, Gunsilius E, Hayes M et al. Low concentrations of STI571 in the cerebrospinal fluid: A case report. Br J Haematol 2002; 117: 623-625.
57. Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 2004; 45: 401-403.
58. Bornhauser M, Jenke A, Freiberg-Richter J et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 2004; 83: 401-402.
59. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
60. Wolff NC, Richardson JA, Egorin M et al. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003; 101: 5010-50103.
61. Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
62. Naito K, Mori T, Miyazaki K et al. Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571). Intern Med 2003; 42: 740-742.